Human epidermal growth factor receptor-2 (HER2)/neu overexpression, a molecular oncodriver in 20–25 % of breast cancers (BC) [1], is associated with an aggressive clinical course and poor overall prognosis [2]. This evidence concerns the gene ERBB2 and breast cancer.